Optimizing Heart Health and Cholesterol Through Functional Medicine

Discover the critical role of cholesterol, genetics, and key biomarkers in maintaining heart health. Functional medicine offers a personalized approach to cholesterol management, helping to reduce cardiovascular risks through a deeper understanding of genetic factors like Apo B, LDL, and PCSK9. Learn how lifestyle changes, nutrition, and targeted medical interventions can create a comprehensive strategy for improving heart health and overall well-being.
Reading Time: 7 minutes

As we observe World Heart Day, it’s a perfect time to delve into the critical biomarkers and genetic factors that influence heart health. In the realm of Functional Medicine, understanding these nuances can lead to more personalized and effective cholesterol management strategies, ultimately reducing cardiovascular risks, and improving your wellbeing.

Is it all about Cholesterol?

The lipid hypothesis, which posits that dietary saturated fat and cholesterol are primary contributors to cardiovascular disease, has been a topic of controversy in the scientific. Please remember the following text: “Nutritionally educated communities.”. Research papers have questioned the validity of this hypothesis, citing inconsistent findings and highlighting the complexity of the relationship between lipids and heart disease (Cundiff et al., 2021). For instance, a study analyzing data from over 7,800 cohorts across 195 countries found that while low-density lipoprotein cholesterol (LDL-C) correlated positively with cardiovascular disease, the association was not solely due to dietary saturated fat and cholesterol (Cundiff et al., 2021).

Cholesterol is indeed an important aspect of heart health, but it is not the sole risk factor for cardiovascular disease. Other crucial considerations include maintaining healthy blood sugar management, avoiding smoking, controlling blood pressure, managing inflammation and oxidative stress, and ensuring a good balance of omega-3 fatty acids and nutrients like Coenzyme Q10 (CoQ10) (Visioli et al., 2020, Liu et al., 2022). A nuanced understanding of these interconnected factors is necessary to develop effective preventive measures and treatment strategies for cardiovascular disease. As emphasized in various research papers, a holistic approach to health, rather than a singular focus on cholesterol reduction, is vital for mitigating cardiovascular risk (Visioli et al., 2020, Liu et al., 2022). By acknowledging the multifaceted nature of heart health, we can move beyond oversimplified notions of “good” and “bad” cholesterol and instead strive for a deeper comprehension of the intricate relationships governing cardiovascular wellness.

With that being said… cholesterol is one of the important pieces of the puzzle and IS relevant for heart health. It also is easier to assess through blood panels and laboratory testing.

Understanding Apolipoprotein B (Apo B)

What is Apo B?

Apolipoprotein B (Apo B) is a protein found on the surface of low-density lipoprotein (LDL) particles, commonly referred to as “bad” cholesterol. Unlike standard cholesterol tests that measure the total amount of LDL cholesterol, the Apo B test quantifies the number of LDL particles in the blood. This distinction is crucial because the number of LDL particles is a more precise predictor of heart disease risk than the total cholesterol content.

The Significance of Apo B

Research shows that individuals with high Apo B levels are at an increased risk for cardiovascular diseases, regardless of the total cholesterol carried by these particles. A higher number of LDL particles increases the likelihood of them penetrating the arterial walls, leading to plaque formation—a process known as atherosclerosis.

How Plaque Formation Happens

When Apo B levels are elevated, it indicates a high number of LDL particles circulating in the bloodstream. These particles can infiltrate the endothelial lining of the arteries and become oxidized, triggering an inflammatory response. Macrophages, a type of white blood cell, engulf the oxidized LDL, transforming into foam cells, which are primary components of arterial plaque. Over time, this plaque buildup narrows the arteries, increasing the risk of heart attacks and strokes.

Monitoring and Managing Apo B

Monitoring Apo B levels provides a more refined approach to assessing cardiovascular risk than traditional cholesterol tests alone. For biohackers and health enthusiasts, managing Apo B levels can be transformative. It allows for targeted interventions that effectively reduce heart disease risk. This might include lifestyle changes, dietary adjustments, and specific medications that impact Apo B levels and LDL particles in the blood.

Leveraging Cardiovascular Genetic Testing

Key Genes: LDLR, PCSK9, and ApoE

Cardiovascular genetic testing is an advanced tool in functional medicine, offering insights into genetic predispositions related to heart health. Key genes such as LDLR, PCSK9, and ApoE significantly influence cholesterol levels and heart disease risk.

  • LDLR Gene: This gene codes for receptors that remove LDL cholesterol from the blood. Mutations can result in high LDL cholesterol levels.
  • PCSK9 Gene: This gene affects the number of LDL receptors available to clear cholesterol. Variants can lead to fewer receptors and higher LDL cholesterol levels.
  • ApoE Gene: Involved in lipid metabolism, different alleles of this gene can affect cholesterol levels and atherosclerosis risk.

Benefits of Genetic Insights

Understanding these genetic factors allows for personalized interventions to mitigate heart disease risk. For instance, individuals with certain PCSK9 gene variants might benefit from PCSK9 inhibitors, a class of drugs that lower LDL cholesterol. Similarly, dietary adjustments can be tailored based on one’s genetic makeup to manage cholesterol levels effectively.

Lifestyle and Environmental Interactions

Armed with genetic information, individuals can make informed decisions about their diets, exercise routines, and stress management techniques. This proactive approach can lead to earlier and more effective interventions, significantly reducing the risk of heart disease.

Combining Apo B and Genetic Testing for Optimal Heart Health

Combining Apo B monitoring with cardiovascular genetic testing provides a comprehensive picture of heart health. This dual approach allows for tailored strategies that address both the number of LDL particles and genetic predispositions, offering a more nuanced understanding of cardiovascular risk.

Practical Steps for Cholesterol Management

Dietary Strategies

  • Reduce Saturated Fat Intake: Saturated fats can increase LDL cholesterol levels. Opt for healthy fats found in fish, nuts, and avocados.
  • Increase Fiber Intake: Dietary fiber helps reduce LDL cholesterol levels. Incorporate plenty of fruits, vegetables, whole grains, and legumes into your diet.
  • Consider Supplements: Supplements such as omega-3 fatty acids, red yeast rice, and plant sterols can help manage cholesterol levels.

Physical Activity and Weight Management

Regular physical activity and maintaining a healthy weight are crucial in managing Apo B levels and overall cardiovascular health. Aim for at least 150 minutes of moderate-intensity exercise per week.

Pharmaceutical Interventions

In some cases, medications may be necessary to manage cholesterol levels effectively. Statins, PCSK9 inhibitors, and other lipid-lowering drugs can be prescribed based on individual needs and genetic predispositions.

Conclusion

By focusing on crucial markers like Apo B and leveraging genetic testing, you can adopt personalized strategies that go beyond traditional cholesterol management. This proactive and informed approach not only enhances health outcomes but also empowers individuals to take control of their heart health, ensuring a longer, healthier life.

Understanding and managing Apo B levels, coupled with insights from cardiovascular genetic testing, can lead to more effective interventions. Whether it’s dietary changes, physical activity, or targeted medications, a personalized approach is key. Embrace this comprehensive strategy to optimize your heart health and reduce your risk of cardiovascular disease.

References

Cundiff, D. K., & Wu, C. (2021). Dietary and other risk factors for cardiovascular disease analysed with Global Burden of Disease worldwide cohorts: lipid hypothesis versus fat-soluble vitamin hypothesis. medRxiv. https://doi.org/10.1101/2021.04.17.21255675

Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019 Dec 1;4(12):1287-1295. doi: 10.1001/jamacardio.2019.3780. PMID: 31642874; PMCID: PMC7369156.

Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. J Am Heart Assoc. 2022 Oct 18;11(20):e025858. doi: 10.1161/JAHA.122.025858. Epub 2022 Oct 10. PMID: 36216435; PMCID: PMC9673669.

Glavinovic T, Sniderman AD. Apolipoprotein B: the Rosetta Stone of lipidology. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):90-96. doi: 10.1097/MED.0000000000000596. PMID: 33229928.

Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ; Convened by the Familial Hypercholesterolemia Foundation. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044. PMID: 30071997.

Medeiros AM, Bourbon M. Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone? Curr Atheroscler Rep. 2023 Apr;25(4):127-132. doi: 10.1007/s11883-023-01091-5. Epub 2023 Mar 2. PMID: 36862327; PMCID: PMC10027780.

Cupido AJ, Reeskamp LF, Hingorani AD, Finan C, Asselbergs FW, Hovingh GK, Schmidt AF. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study. JAMA Cardiol. 2022 Sep 1;7(9):955-964. doi: 10.1001/jamacardio.2022.2333. PMID: 35921096; PMCID: PMC9350849.

Visioli F, Poli A. Fatty Acids and Cardiovascular Risk. Evidence, Lack of Evidence, and Diligence. Nutrients. 2020;12(12):3782. Published 2020 Dec 9. doi:10.3390/nu12123782

Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016 Jul;94(7):739-46. doi: 10.1007/s00109-016-1427-y. Epub 2016 Jun 9. PMID: 27277824; PMCID: PMC4921111.

Liu X, Harding SV, Rideout TC. Saturated Fat and Cardiovascular Health: Phenotype and Dietary Factors Influencing Interindividual Responsiveness. Curr Atheroscler Rep. 2022;24(5):391-398. doi:10.1007/s11883-022-01014-w

Want to schedule and appointment but unsure about your coverage? Easily find out by using our contact us form. We will check your coverage and send you the results!

Contact Us

Related Articles

© 2022 Vida Integrated Health. All Rights Reserved.
This website uses cookies for Marketing Purposes. To learn more, see our Privacy Policy.

LOCATIONS

Seattle

Ravenna

Bellevue

Kirkland

Everett